Showing posts with label Chronic Lymphocytic Leukemia. Show all posts
Showing posts with label Chronic Lymphocytic Leukemia. Show all posts

Thursday, 2 May 2019

Chronic Lymphocytic Leukemia: Upcoming Trends, Growth Drivers, Opportunities and Challenges Epidemiology Forecast to 2027

Researchmoz added Most up-to-date research on "Chronic Lymphocytic Leukemia: Epidemiology Forecast to 2027" to its huge collection of research reports. An insight on the important factors and trends influencing the market.
Chronic lymphocytic leukemia (CLL) (International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] code = C91.1), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.
Download Exclusive Free Sample Of This Report: https://www.researchmoz.us/enquiry.php?type=S&repid=1978230
GlobalData epidemiologists utilized national databases and robust peer-reviewed journal articles to build the CLL diagnosed incident and diagnosed prevalent cases forecast for the 7MM. The disease definition for CLL was consistent with the ICD-10 code C91.1. Whenever available, country-specific sources were utilized. In cases of data scarcity, appropriate proxies were used to fill the data gaps.
The diagnosed incident cases of CLL in the 7MM will increase from 41,974 cases in 2017 to 50,474 cases in 2027, at an Annual Growth Rate (AGR) of 2.03% over the forecast period. For the majority of the forecast period, the US will have the highest number of diagnosed incident cases of CLL. GlobalData epidemiologists attribute the growth in the diagnosed incident cases of CLL in the 7MM to the moderately rising trend in incidence in the 7MM, combined with the changing population demographics in the respective markets.
Scope
- The Chronic Lymphocytic Leukemia (CLL) Epidemiology Report provides an overview of the risk factors and global trends of CLL in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada).
- The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CLL segmented by age (for ages 18 years and older) and sex. The CLL diagnosed incident cases are segmented by Rai stage, modified Rai stage, and Binet stage at diagnosis, as well as high-risk cytogenetics for the 7MM. Additionally, GlobalData epidemiologists provide a forecast for the diagnosed prevalent cases of CLL in the 7MM. To forecast the diagnosed incident and diagnosed prevalent cases of CLL in the 7MM, GlobalData epidemiologists used data from nationally representative, population-based studies for the 7MM.
- The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Contact For Discount or to Get Customized Report: https://www.researchmoz.us/enquiry.php?type=E&repid=1978230
Reasons to buy
The CLL Epidemiology report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CLL market.
- Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CLL therapeutics in each of the markets covered.
- Understand magnitude of CLL patient population by stage.
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us

For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

Wednesday, 3 May 2017

Global CLL Therapeutics Market To Grow At A CAGR Of 19.16% During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports.

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=729302

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=729302

Monday, 23 January 2017

At A CAGR Of 19.16% CLL Therapeutics Global Industry Will Grow Steadily During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports.

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=729302

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=729302

Thursday, 19 January 2017

At A CAGR Of 19.16% CLL Therapeutics Global Industry Will Grow Steadily During The Period 2016-2020

Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports.

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=729302

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=729302

Blood Thawing System Market Insights Shared in Detailed Report

Blood Thawing System Market: Introduction According to the report, the global  blood thawing system market  was valued at ~US$ 174 Mn in 2...